COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Studying the need of medical treatment together with removal of the testes surgically to treat men with late cancer of prostate.
Scientific title
Is Combined Androgen Blockade by Surgical Castration and Flutamide Necessary as an Initial Therapy for Patients with Advanced Prostate Cancer? A randomized clinical trial.
Secondary ID [1] 294305 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate cancer 307393 0
Condition category
Condition code
Cancer 306105 306105 0 0
Surgery 306549 306549 0 0
Surgical techniques

Study type
Description of intervention(s) / exposure
Patients with advanced prostate cancer were randomized into two groups after being subjected to surgical castration by bilateral simple orchidectomy . The duration of surgery was about 30 minutes. Group I was followed up for disease progression after orchidectomy alone.Group II patients also had underwent bilateral simple orchidectomy but additionally they were given oral flutamide 250 mg tablets three times daily after meals for up to two years and were followed up. Bilateral simple Orchidectomy for both groups was done by scrotal approach under spinal anesthesia . The patients were asked to return the drug tablet to ensure adherence to the intervention.The follow up period was up to two years following orchidectomy for both groups.
Intervention code [1] 300606 0
Treatment: Other
Comparator / control treatment
Group I patients who underwent orchidectomy only was considered as the comparator reference group.
Control group

Primary outcome [1] 305136 0
Percent change in values of PSA . Levels of PSA were assessed by serum assay for all patients.
Timepoint [1] 305136 0
One month , two month and three months following orchidectomy ( primary endpoint ) . The serum PSA was assessed at the end of first month , second month and third month following orchidectomy to detect the maximum percent change in serum PSA.
Primary outcome [2] 305505 0
Percent change in levels of serum testosterone were assessed by serum assay.
Timepoint [2] 305505 0
One month , two month and three months following orchidectomy ( primary endpoint ) . The serum testosterone was assessed at the end of first month , second month and third month following orchidectomy to detect the maximum percent change in serum testosterone.
Secondary outcome [1] 344293 0
Percent change in serum PSA at the end of second year following orchidectomy
Timepoint [1] 344293 0
This outcome will be assessed a single time at the end of the second year following orchidectomy .
Secondary outcome [2] 345512 0
This is a composite outcome by checking for disease spread to distant organs despite initiation of therapy.This was measured by detection of new metastasis in bone , liver or other organs by doing Ct scan of abdomen and bone radiology,
Timepoint [2] 345512 0
This outcome was assessed a single time at the end of the second year following orchidectomy for both groups.

Key inclusion criteria
Patients with advanced prostate cancer
Minimum age
55 Years
Maximum age
75 Years
Can healthy volunteers participate?
Key exclusion criteria
patients with local disease or severe co-morbidities .

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization by giving patients numbers at time of recruitment , then patients with odd numbers were allocated to group I and those with even numbers to group II.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
Analysis of variance ( ANOVA ) was used to analyze the differences among groups mean and percentage.

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 9675 0
State/province [1] 9675 0

Funding & Sponsors
Funding source category [1] 298951 0
Name [1] 298951 0
Basrah General Hospital
Address [1] 298951 0
Iraq- Bsarah - Hayy Al Kafaat , St. no. 12 near Saad Sq.
Country [1] 298951 0
Funding source category [2] 298952 0
Name [2] 298952 0
Basrah University
Address [2] 298952 0
Iraq - Basrah - al -Bradehia St. no 10
PO. Box 953
Country [2] 298952 0
Primary sponsor type
Basrah university
Iraq - Basrah al Bradehia St. no 10
PO. Box 953
Secondary sponsor category [1] 298164 0
Name [1] 298164 0
Address [1] 298164 0
Country [1] 298164 0

Ethics approval
Ethics application status
Ethics committee name [1] 299888 0
Basrah college of medicine
Ethics committee address [1] 299888 0
Iraq - Basrah al Bradheia
Ethics committee country [1] 299888 0
Date submitted for ethics approval [1] 299888 0
Approval date [1] 299888 0
Ethics approval number [1] 299888 0

Brief summary
Prostate cancer is still a common disease worldwide. It can lead to death. Many ways to for treating this disease do exist. This study aimed to compare two ways of treatment of this disease especially when it's advanced or late. Men aged 55 to 75 years were included in this study. All of them were having prostate cancer at a late stage. All patients had underwent surgical removal of both testes. However, some of the patients in the study were given a specific drug for Prostate cancer as additional treatment way. Both groups of men were followed for their response to the surgery alone or to the surgery with medicine to discover how they differ in their improvement state. The main goal was to know whether it is useful to give the patients medical treatment beside the surgery to control their disease. The men in the study were real patients and they were offered the necessary treatment after taking their consent. No major serious bad events were expected to occur for them as a result of these treatments apart from the effect of their cancer. About 60 men were included in the study which was done in Iraq at Basrah Teaching Hospital in Basrah city. The study started in 2012 and continued for about 5 years. However, for each individual patient the period of involvement in the study was about two years.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 81874 0
A/Prof Firas Shakir Attar
Address 81874 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah College of medicine .
Country 81874 0
Phone 81874 0
Fax 81874 0
Email 81874 0
Contact person for public queries
Name 81875 0
A/Prof Firas Shakir Attar
Address 81875 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah college of medicine .
Country 81875 0
Phone 81875 0
Fax 81875 0
Email 81875 0
Contact person for scientific queries
Name 81876 0
A/Prof Firas Shakir Attar
Address 81876 0
Iraq -Basrah 1135 - 42001 Ashar. Basrah college of medicine .
Country 81876 0
Phone 81876 0
Fax 81876 0
Email 81876 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary